To sum up, anti-PD-1/PD-L1 ICI monotherapy is beneficial for NSCLC patients with BMs, which can diminish intracranial disease, reduce adverse events and improve survival, particularly for those with high PD-L1 expression (Table 1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.